The efficacy of external Trigeminal Nerve Stimulation (TNS) in youth with Attention-Deficit/Hyperactivity Disorder (ADHD): a multi-centre, double-blind, randomized, sham-controlled, parallel-group, phase IIb trial
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
External trigeminal nerve stimulation (TNS) received FDA clearance in 2019 as the first device-based, non-pharmacological treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), based on a small pilot sham-controlled randomized controlled trial (RCT) that reported symptom improvement in 62 children with ADHD. We conducted a confirmatory multi-centre, double-blind, randomized, sham-controlled, parallel-group, phase IIb RCT investigating short and longer-term efficacy (6 months) of real vs sham TNS in 150 children and adolescents with ADHD. Partricipants were randomized to receive real TNS ( n =75, mean age [ SD ]= 12.6 [2.8 years]), or sham TNS ( n =75, mean age [ SD ]= 12.6 [2.8 years]), nightly for 4 weeks. Bilateral stimulation targeted V1 trigeminal branches using battery-powered electrodes applied to the forehead for ~9 hours/night. Sham TNS delivered 30 seconds of stimulation per hour at a lower frequency. Intention to treat analysis (ITT) showed no significant differential treatment effects on ADHD symptoms (estimated adjusted mean difference [ aMD ] = 0.83; 95% Confidence interval [CI] = –2.47 to 4.13; p = 0.622; Cohen’s d = 0.09). No differential treatment effects were observed either on the secondary outcomes covering other symptom scales of ADHD and related clinical problems, as well as cognitive and physiological outcomes, except for a small reduction in mind wandering favouring real TNS ( aMD = –2.17; 95% CI = –4.33 to –0.01; p = 0.049; Cohen’s d = –0.27). Adherence was 94% and compliance 93%. Blinding was successful. No serious adverse events (SAEs) were reported, and side effects did not differ between groups. In conclusion, TNS is a safe intervention but does not demonstrate clinical efficacy for paediatric ADHD. Trial registration: ISRCTN82129325.